It’s only fair to share… Sunvozertinib CAS 2370013-12-8 DZD9008, 584.1 g/mol, C29H35ClFN7O3, A-1801, L1Q2K5JYO8 N-[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide FDA Zegfrovy, 7/2/2025 To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy Sunvozertinib (DZD9008) is a potent ErbBs (EGFR, …